[S-phase cells of human bladder tumors by in vivo bromodeoxyuridine labeling].
At the time of operation, 10 patients with bladder tumors were given an intravenous infusion of bromodeoxyuridine (BrdU, 250 mg) to label the cells in the DNA synthesis phase (S-phase). The removed tumor specimens were stained immunohistologically using anti-BrdU monoclonal antibody. The percentage of BrdU-labeled cells (S-phase cells) were calculated for each specimen, and expressed as Labeling Index (LI). The average LI of G1, G2 and G3 tumors were 0.9%, 2.3% and 11.9%, respectively. LI was almost parallel to pathological grade. In cases of G2 tumor, LI was varied from 0.2 to 6.2%. The higher LI, the more invasive was the tumor. The patient with the highest LI (12.2%) showed lung metastasis postoperatively and died 6 months after operation. S-phase cells were scattered along the basal layer in G1 papillary tumors, and were observed also near the superficial layer in G2 tumors. In cases of non-papillary tumors, S-phase cells were observed irregularly in various layers. This method will give us useful information on evaluation for malignancy and cell kinetics of bladder tumor.
Ohyama
C
C
Department of Urology, Tohoku University School of Medicine.
Nakazumi
H
H
Satoh
M
M
Yoshikawa
K
K
Hoshi
S
S
Orikasa
S
S
Hayashi
T
T
Mituno
S
S
Murakami
F
F
Kurosu
S
S
D000368:Aged; D000369:Aged, 80 and over; D001973:Bromodeoxyuridine / Q000008:administration & dosage; D002295:Carcinoma, Transitional Cell / Q000473:pathology*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007262:Infusions, Intravenous; D007399:Interphase; D008297:Male; D008875:Middle Aged; D001749:Urinary Bladder Neoplasms / Q000473:pathology*
D001973:Bromodeoxyuridine